Kornimate/medical-research-clean huggingface dataset:
a study of revian red all led cap as a novel treatment for central centrifugal cicatricial alopecia

Conditions: Central Centrifugal Cicatricial Alopecia

Summary: the purpose of this study is to determine if the revian red all led cap shows potential to be an effective treatment for central centrifugal cicatricial alopecia (ccca) by recruiting hair follicles back to anagen growth or by improving inflammation. the primary outcome is to determine if hair loss regression is halted. secondary outcomes include hair regrowth and alleviation of signs and symptoms of the disease. participants will be asked to use the revian red all led cap once daily for a 10-minute treatment regimen which is the current androgenetic alopecia recommendation.

subjects who are willing to participate in a novel treatment for revian red all led cap will be enrolled in this study. the cap uses two wavelengths of light, 620 nm and 660 nm. a study cap will be provided for each subject. subjects will use the cap once daily, 10-minute treatment regimen which is the current androgenetic alopecia recommendation. the subjects will use the cap for a total of 6 months. to use the cap, subjects will connect the revian red all led cap to a smart app on a mobile phone device using bluetooth. subjects can use the smart app to set daily reminders to use the cap, track and log usage, and use the 10 minute timer. no additional information will be stored on the smart app. only subjects will have access to the smart app located on their personal mobile phone device. standardized photos and trichoscopic photos before starting treatment and every 2 months for x 6 total months will be taken to assess hairline stabilization and potential for regrowth. a baseline photo and completion photo will also be taken with a visio device. this will help determine pigmentation of the present hairs throughout the study. prior to study enrollment, all participants will receive a detailed explanation of the purpose of the study and will undergo written informed consent. clinical history of hair loss and history of prior treatment will be obtained by administering a standardized questionnaire to all subjects. subjects will also fill out a questionnaire regarding symptoms of their hair loss at each visit. there will be 4 visits total (1 pre-treatment visit and 3 follow up visits).

Eligibility criteria:
inclusion criteria: * women who are between the age of eighteen years and sixty-five years * biopsy-proven diagnosis of ccca stage ii-iv. * must be on stable treatment without changes (on doxycycline, topical steroids, minoxidil and/or post 8 rounds of intralesional steroids) for at least 3 months exclusion criteria: * subjects with other forms of hair loss that is not ccca * prior treatment with light source for alopecia * males are excluded from this study since the prevalence of ccca in males is so significantly low that it is difficult to find cases in a clinical setting

Keywords: hair loss scalp symptoms
improvement of the performance of lumbar punctures after training students with an augmented reality simulator

Conditions: Lumbar Puncture

Summary: lumbar punctures (lp) are frequent invasive procedures that are anxiety-provoking for both the patient and the clinicans performing the procedure. lp is performed by many practitioners, whether they are emergency physicians, neurologists, neurosurgeons, internists or rheumatologists. learning how to perform lp is essentially done at the patient's bed by showing the students how a procedure is performed and then having them perform it directly on a patient afterwards. the recent development of simulation in health care with the credo "never the first time on the patient" requires the development of training devices faithful to reality. the rheumatology department of the strasbourg university hospital has been working for 3 years, in collaboration with the strasbourg start-up insimo, on the development of an lp simulator. this simulator is original because it allows the feeling by pressure of the passage of the various structures, and in particular the yellow ligament. this sensation is made possible by a haptic force feedback device.


Eligibility criteria:
inclusion criteria: * requiring a lumbar puncture as part of their routine care * male or female of legal age with no upper age limit * french speaking * subject affiliated to a social health insurance scheme * not having expressed his or her opposition to the re-use of his or her data in the context of this research exclusion criteria: * previously undergone a lumbar puncture * bmi \> 35 kg/m². * spinal ankylosis: history of ankylosing spondylitis or forestier's disease * impossible to give the subject informed information (subject in an emergency situation, difficulties in understanding the subject, etc.) * subject under court protection * subject under guardianship or curatorship * contraindication to the use of emlapatch

Keywords: lumbar puncture simulator
optimizing door-to-reperfusion times of one-stop management in acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: time is one of the most important in the decision of treatment of acute ischemic stroke. the optimal one-stop management from admission to recanalization associated with reduction of in-hospital times. the development of ﬂat-detector computed tomography perfusion capable angio-suite allowed one-stop management to be improved treatment time better and better. to compare one-stop management versus our standard workflow in shortening door-to-recanalization time.

acute ischemic stroke is one of the diseases associated with stroke onset time, especially in the case of large vessel occlusion within 6 hours. this is the reason why endovascular reperfusion therapy (mechanical thrombectomy, angioplasty, stent,...) is recommended to be performed as soon as possible in the comprehensive stroke centers. the successful recanalization within 6 hours demonstrated the efficacy that helps to improve the functional outcome by trials. besides, the strategies shortening time from admission to successful recanalization are essential for the treatment of acute ischemic stroke due to large vessel occlusion. nevertheless, the optimizing door-to-groin puncture and door to recanalization time are the great challenge to benefit most patients with the endovascular therapy. in recent years, the one - stop management (direct transport to the angiosuite workflow) which means that the recanalization therapy is considered to perform immediately based on the diagnostic angiograms and perfusion maps relating to acute ischemic stroke caused by large vessel occlusion by the ﬂat-detector computed tomography at the angiosuite at the same time. we hypothesized that one-stop management is feasible and reduces more intrahospital time delays than our standard workflow previously published.

Eligibility criteria:
inclusion criteria: * acute ischemic stroke in the anterior circulation caused by large vessel occlusion. * national institute of health stroke scale (nihss) ≥10. * premorbid modified rankin scale (mrs) ≤ 2 * target mismatch profile: cbf \ 1.8. * available angiosuite. * cbf \< 30% volume: 70 - 100 ml when non-contrast computed tomography (ncct) alberta stroke program early computed tomography scores (aspects) was 3 - 5 and/or beyond 6 hours after symptom onset exclusion criteria: * evidence of intracranial tumors, the encephalitis, the hemorrhage: either an intracranial hemorrhage (ich) or subarachnoid hemorrhage (sah) by the biplane flat panel detector computed tomography. * participated in another studies. * loss to follow-up after discharge. * a severe or fatal combined illness before acute stroke.

Keywords: acute ischemic stroke angiosuite reperfusion times one-stop
pregnancy and neonatal follow-up of ongoing pregnancies established in clinical trial p05693 (p05713)

Conditions: Pregnancy; Neonates

Summary: the objective of follow-up study p05713 is to evaluate whether corifollitropin alfa (org 36286) treatment for the induction of monofollicular growth in women who underwent ovulation induction (oi) in base study p05693 (nct00697255) is safe for pregnant participants and their offspring.

base study p05693 (nct00697255) was planned to include two separate stages (ia+ib and ii). stage ia was open-label and uncontrolled in a small cohort of women (n=5) to explore whether the intended dosing regimen of corifollitropin alfa followed by daily low dose recombinant follicle stimulating hormone (recfsh) would provide an appropriate response in eligible participants meeting all inclusion and none of the exclusion criteria. stage ib was open-label and uncontrolled in a small cohort of women (n=3) to explore whether the intended dosing regimen of corifollitropin alfa followed by daily low dose human chorion gonadotropin (hcg) would provide an appropriate response in eligible participants meeting all inclusion and none of the exclusion criteria. stage ii was planned to be open-label and randomized (n=40) to evaluate whether the intended dosing regimen of corifollitropin alfa followed by low dose recfsh (n=20) or hcg (n=20) would provide an appropriate response in eligible participants meeting all inclusion and none of the exclusion criteria. p05713 is a follow-up (fu) study to prospectively monitor pregnancy, delivery, and neonatal outcome of women who became ongoing pregnant during base study p05693 (nct00697255). for this trial, no study specific assessments will be required and no treatment will be administered, but information as obtained in standard practice will be used. enrollment will begin when the first ongoing pregnancy resulting from the base study has been established (ultrasound ≥ 10 weeks after bolus injection of hcg).

Eligibility criteria:
inclusion criteria: * participants who participated in base study p05693 (nct00697255) and received at least one dose of corifollitropin alfa * ongoing pregnancy confirmed by ultrasound at least 10 weeks after bolus injection of hcg in base study p05693 * able and willing to give written informed consent (informed consent is incorporated in the informed consent form of protocol p05693) exclusion criteria: * none

Keywords: neonatal outcome congenital malformations ovulation induction follow-up
monitoring of piperacillin-tazobactam and meropenem plasmatic levels in critical patients

Conditions: Sepsis; Septic Shock

Summary: the aim of this study is to establish the piperacillin-tazobactam and meropenem plasmatic levels to know if it´s necessary to make some adjustment in the recommended dose regimen.


Eligibility criteria:
inclusion criteria: * patients above 18 years old. * hospitalized in the intense care unit. * patients treated with piperacillin-tazobactam or meropenem. * septic shock. * renal hyper clearance. * gram-negative bacillary bacteremia. * continuous renal replacement technique. * ecmo. * obesity (bmi\> 40). exclusion criteria: * patients under 18 years old. * pregnant women.

Keywords: sepsis septic shock piperacillin-tazobactam meropenem plasmatic levels critical patients dose adjustment
a comparison of propofol based total intravenous anesthesia and desflurane based balanced anesthesia on hepatic protection during living-donor liver transplantation

Conditions: End Stage Liver Disease

Summary: renal ischemia/reperfusion (i/r)-induced injury is known to be associated with immediate and long-term hepatic dysfunction after liver transplantation. protecting the liver against i/r injury and maintaining hepatic function during transplant surgery is therefore very important in order to improve post-operative outcome. this purpose of this study is to investigate whether propofol anesthesia done in both liver donors and recipients during living-donor liver transplantation is effective in reducing liver i/r injury via its antioxidant and antiinflammatory properties and improve post-transplant outcome compared to desflurane anesthesia.


Eligibility criteria:
inclusion criteria: (1) adult liver donors and recipients scheduled for liver transplantation exclusion criteria: 1. patient refusal 2. hypersensitivity to propofol, soybeans or peanuts 3. history of vitamin c or e intake within 5 days before surgery 4. history of acute myocardial infarct within 6 months before surgery 5. congestive heart failure (nyha iii-iv) 6. autoimmune disease patients 7. bmi over 30 kg/m2 8. left ventricular ejection fraction less than 35% upon preoperative echocardiography
a pilot study to evaluate the effect of a probiotic mixture in acne

Conditions: Acne; Acne Vulgaris

Summary: a 12-week randomized, double-blind, placebo-controlled pilot study to evaluate the effect of a probiotic blend in the treatment and clinical and subjective evolution of acne vulgaris in adolescent and adult patients between 12 and 30 years.


Eligibility criteria:
inclusion criteria: * signature of informed consent by the patient (and their legal guardian in case of being under age). * age between 12 and 30 years-old. * moderate acne according to the agss (acne global severity scale) and / or gags (global acne grading system) scales. exclusion criteria: * contraindication of any of the components of the product under study. * topical or systemic use of antifungals and antibiotics in the previous 2 weeks. * consumption of probiotics in the previous 2 months. * use of systemic retinoids in the previous 6 months.

Keywords: probiotic
pilot study for the early detection of chronic kidney disease, non-dialysis objective (ndo).

Conditions: Chronic Kidney Disease (CKD)

Summary: chronic kidney disease (ckd) is a significant public health problem worldwide, affecting more than 10% of the spanish population. early detection is considered a top healthcare priority to establish strategies for preventing progression to more advanced stages of the disease and its complications. additionally, ckd is associated with high comorbidity, poor prognosis, and substantial resource consumption within the healthcare system. in this context, albuminuria may be a more sensitive marker of ckd than reduced glomerular filtration rate (gfr), and it is also considered an indicator of not only renal damage but also \&#34;systemic damage\&#34; (generalized endothelial dysfunction, arterial remodeling, and increased cardiovascular risk) beyond the kidney. furthermore, the reduction of proteinuria/albuminuria is clearly associated with a slower progression of ckd, making its reduction a therapeutic goal as well. given this importance, this protocol aims to determine the urine albumin/creatinine ratio in all patients over 18 years old who visit their primary care physician in the province of burgos, spain, and require a blood test related to their reason for consultation.

this is a protocol in which we seek to identify those patients with alterations incipient renal failure by determining the albumin/creatinine ratio in urine, test that is currently performed routinely in different groups of patients. by for this reason, the implementation of the non-dialysis objective protocol hopes to be implemented standardized form in patients who go to their primary attention doctor in the province of burgos to later be extended to the entire castilla y leon community. .

Eligibility criteria:
inclusion criteria: * minimum age 18 years exclusion criteria: * age less than 18 years

Keywords: epidemiology. chronic kidney disease. primary care. cardiovascular risk factors.
autologous muscle derived cells for female urinary sphincter repair

Conditions: Stress Urinary Incontinence

Summary: this randomized, double-blind, placebo-controlled, multicenter, confirmatory study will evaluate the efficacy and safety of cook myosite incorporated autologous muscle-derived cells (generic name iltamiocel) compared to a placebo (vehicle) control dose in the treatment of stress urinary incontinence (sui) in adult female patients.

study comparing intrasphincteric injection of iltamiocel with placebo. subjects unblinded after 12 month visits, but followed for up to 2 years. subjects randomized to placebo could elect to receive open-label iltamiocel after completing 12 month visit.

Eligibility criteria:
inclusion criteria: * female patient has primary symptoms of sui, as confirmed by patient medical history and clinical symptoms, including a focused incontinence evaluation. exclusion criteria: * patient has symptoms of pure urge incontinence as confirmed by basic evaluation of etiology from a patient medical history, including a focused incontinence history. * patient has symptoms of mixed urinary incontinence where urge incontinence is the predominant factor. * patient has had stress urinary incontinence symptoms less than 6 months prior to signing the informed consent. * patient has not previously attempted conservative treatment prior to signing the informed consent. (examples of conservative treatment include behavior modifications, bladder exercises, biofeedback, etc.) * patient has more than 2 episode of awakening to void during normal sleeping hours. * patient cannot be maintained on a stable dose and/or frequency of medication (including diuretics) known to affect lower urinary tract function, including but not limited to, anticholinergics, tricyclic antidepressants or alpha-adrenergic blockers, for at least 2 weeks prior to screening or is likely to change during the course of the study. * patient is pregnant, lactating, or plans to become pregnant during the course of the study. * patient refuses to provide written informed consent. * patient is not at least 18 years of age. * patient is not available for the follow-up evaluations as required by the protocol.

Keywords: urinary incontinence, stress tissue therapy (cell therapy) transplantation, autologous
newly-diagnosed intermediate/high risk pediatric b-cell all protocol

Conditions: Acute Lymphoblastic Leukemia ALL; Childhood Leukemia, Acute Lymphoblastic; B Cell Acute Lymphoblastic Leukemia (B-ALL)

Summary: building upon the results from the cccg-all-2015, cccg-all-2020 multicenter study cohort, concurrent research findings, and the latest clinical trials, the cccg-all-2025 i/hr-b-all is thus developed to further improve the event-free survival (efs), and overall survival (os), and quality of life (qol) of children with intermediate- and high- risk b-cell childhood acute lymphoblastic leukaemia (i/hr-b-all), while decreasing adverse reactions and transplantation rates. this trial primarily aims to explore: 1. the efficacy of two randomized blinatumomab application scheme on i/hr-all as determined by mrd negatvitiy rate. 2. the efficacy of modified mini-hypercvd + venetoclax in i/hr-all cannot afford blinatumomab, in contrast to historical control as determined by mrd negatvitiy rate.

the study shown above will lead to the following revisions to the cccg-all2025 i/hr-b-all plan, which will be based on the cccg-all2020 plan. 1. after the induction remission phase, all i/hr-b-all patients can afford blinatumomab will participate in a blinatumomab+hdmtx randomized controlled trial as consolidation. 2. for patients cannot afford blinatumomab will be treated with venetoclax + modified mini-hypercvd during the induction phase, then subsequently with cat as consolidation phase. cat will removed from induction phase. 3. for patients who received blinatumomab randomization, the cat+ course was canceled. 4. all patients will continued with 6 cycles of alternated 5-day venetoclax or dauno-based cccg-2020 continuous therapy regimen. 5. adding igh rearrangement ngs mrd as an evaluation indicator. 6. adding pharmacotyping study for i/hr b-all. 7. three more bone marrow punctures and it will be added with the aims to evaluate the cr rate with deepen remission during or after consolidation.

Eligibility criteria:
inclusion criteria: 1. age older than 1 month to younger than 18 years. 2. diagnosis of acute lymphoblastic leukemia by bone marrow morphology. 3. diagnosis of b-all by immunophenotyping. exclusion criteria: 1. low-risk all 2. sigm+ 3. acute leukemias of ambiguous lineage diagnosed according to who or egil criteria. 4. all evolved from chronic myeloid leukemia (cml). 5. down's syndrome, or major congenital or hereditary disease with organ dysfunction 6. secondary leukemia 7. known underlying congenital immunodeficiency or metabolic disease 8. congenital heart disease with cardiac insufficiency. 9. treated with glucocorticoids for ≥14 days, or abl kinase inhibitors for \> 7 days within one month before enrollment, or any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)

Keywords: blinatimomab venetoclax
the effect of listening to surah inshirah on mental health in hemodialysis patients.

Conditions: Hemodialysis Patients

Summary: in addition to physical symptoms, mental, social and economic problems may also occur in patients receiving hemodialysis treatment. the most prominent among these problems are psychological problems. it is known that depression and anxiety levels are high in hemodialysis patients.non-pharmacological methods reduce the patient's pain and anxiety by creating a feeling of comfort and control in the patient. relaxation techniques such as hypnosis, yoga and music are among these. the main purpose of these methods is to draw the attention of the individual in another direction. praying is also one of the non-drug methods, and the number of studies on this subject is very limited, and there are studies where it has been determined that praying and praying reduces the anxiety levels of patients.purpose: to examine the effect of listening to surah inshirah on depression, anxiety, stress and mental well-being of hemodialysis patients during treatment. method: the population of the research will consist of hemodialysis patients who are treated at mardin training and research hospital, meet the inclusion criteria and volunteer to participate in the research. the study group of 60 people who will participate in the research will be divided into two equal groups according to the table of random numbers obtained from the computer-based research randomizer program. experimental group patients; a patient descriptive characteristics form will be applied, and the pre-test depression, anxiety, stress and mental well-being scale will be applied. then, surah inshirah will be listened to and the final test, the depression, anxiety, stress and mental well-being scale, will be applied. control group patients; a patient descriptive characteristics form will be applied, and the depression, anxiety, stress and mental well-being scale will be applied. the final test will be applied to the depression, anxiety, stress and mental well-being scale without any intervention.


Eligibility criteria:
inclusion criteria: * patients who can be contacted,patients aged 18 and over were included in the study. exclusion criteria: * patients aged 18 and over were included in the study.